TP53 and cancer: Whilst p53 levels were increased by ~1.7 fold by [L2Cu3]6+ and ~2.7 fold by [L2Zn3]6+ treatment in the HCT116 cancer cells, levels of p53 actually decreased with treatment in the ARPE19 non-cancer cells further indicating differential effects of the complexes on cancer versus non-cancer cells (Fig. 10).